Ocular Therapeutix (OCUL) Liabilities and Shareholders Equity (2013 - 2026)

Ocular Therapeutix's Liabilities and Shareholders Equity history runs 14 years deep, the most recent figure standing at $732.5 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 80.46% year-over-year to $732.5 million; the TTM figure through Mar 2026 stood at $2.4 billion (up 28.4% YoY), while the FY2025 annual figure was $808.1 million, up 76.46% from the prior year.
• Liabilities and Shareholders Equity was $732.5 million for Q1 2026 at Ocular Therapeutix, down from $808.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $808.1 million in Q4 2025 to a low of $122.6 million in Q2 2023.
• Historically, Liabilities and Shareholders Equity has averaged $361.6 million across 5 years, with a median of $405.9 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity plunged 31.47% in 2023, then soared 321.92% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $149.3 million in 2022, then soared by 68.84% to $252.1 million in 2023, then surged by 81.68% to $457.9 million in 2024, then jumped by 76.46% to $808.1 million in 2025, then decreased by 9.35% to $732.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $732.5 million (Q1 2026), $808.1 million (Q4 2025), and $410.9 million (Q3 2025), per Business Quant data.